Month: January 2022

Next generation of Evoca products provides commercial potential at 2026 horizon Ghent, Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) — Press release Biotalys Achieves Breakthrough in Protein Expression Increasing Commercial Potential for its first BioFungicide Evoca Next generation of Evoca products provides commercial potential at 2026 horizon Ghent, BELGIUM – 25 January 2022, 07:00 CET – Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, today announced it has achieved a breakthrough in protein expression of the bioactive ingredient of its first biocontrol product Evoca™*. The breakthrough announced today has the potential to transform Evoca from a market calibration tool into a product providing commercial value at competitive efficacy and...

Interim data submitted to the FDA show majority of pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowing Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting,...

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — Keyarch Acquisition Corporation (the “Company”) announced today that it priced its initial public offering of 10,000,000 units at a price of $10.00 per unit. The Company has granted the underwriters a 45-day option to purchase up to 1,500,000 units to cover over-allotments, if any. The units are expected to commence trading on January 25, 2022 on The Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “KYCHU.” Each unit consists of one Class A ordinary share of the Company, one-half of one redeemable warrant and one right to receive one-tenth of one Class A ordinary share. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the...

Vancouver, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQX: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) announces that it has awarded a total of 5,611,843 restricted share units to various employees, executives, directors, and consultants of the Company on the basis of the 5-day volume-weighted average price on the TSX Venture Exchange and pursuant to a new Share Compensation Plan to be approved by shareholders at an upcoming shareholders’ meeting. A portion of the restricted share units vest based on the underlying share price performance over a three-year measurement period from the award date. A further portion of the restricted share units will vest annually over a three-year period from the award date. A further portion of the restricted share units was granted to Non-Executive...

No Shareholder Action Required at This Time NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — WisdomTree Investments, Inc. (NASDAQ: WETF), an exchange-traded fund (“ETF”) and exchange-traded product (“ETP”) sponsor and asset manager, today issued the following statement in response to the Schedule 13D filed today with the U.S. Securities and Exchange Commission by WisdomTree shareholder ETFS Capital Limited: The WisdomTree Board of Directors welcomes and encourages open communications with its shareholders and values their input. We are committed to enhancing value for all shareholders and will continue to take actions that we believe will enable us to achieve this objective. Our shareholders need take no action at this time. Advisors Goodwin Procter LLP is serving as legal counsel to WisdomTree. Innisfree M&A is serving as proxy...

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this week. The three-day event, in association with London Stock Exchange, global law firm Taylor Wessing and OpenExchange, will take place between January 25-27th, focusing on 33 companies. Mesoblast will feature on Day one – Businesses within Pharmaceuticals & Drug Discovery. Content will be available to stream from 8am GMT on Tuesday, January 25th. Attendance is free and anyone wanting to attend can sign up here: https://www.edisongroup.com/event/edison-open-house-global-healthcare-2022/ For any questions about the event or how to register, please reach...

Highlights:Euro Manganese to settle the balance of the outstanding amounts due under the Royalty Termination Agreements with payment of US$1.8 million in cash and the issuance of 4,820,109 common shares valued at CAD$2,278,080 (US$1.8 million)VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) —  Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the “Company” or “EMN”) is pleased to announce that, further to its announcement of May 31, 2021, it intends to issue 4,820,109 common shares (“Shares“) as partial consideration to purchase and extinguish the aggregate 1.2% net smelter royalty (“NSR“) interest in the Chvaletice Manganese Project. Pursuant to the royalty termination agreements (the “Royalty Termination Agreements“) dated May 31, 2021, the Company agreed...

Preliminary Financial Results and Other Matters for the Quarter and Year Ended December 31, 2021:CECL Adoption: As previously disclosed, effective January 1, 2021, Great Southern Bancorp, Inc. (the Company) adopted the Current Expected Credit Loss (CECL) accounting standard. The Company’s financial statements for periods prior to January 1, 2021, were prepared under the incurred loss accounting standard. The adoption of the CECL accounting standard during the first quarter of 2021 required us to recognize a one-time cumulative adjustment to our allowance for credit losses and a liability for potential losses related to the unfunded portion of our loans and commitments in order to fully transition from the incurred loss model to the CECL model. Significant Income and Expense Items: During the three months ended December 31, 2021, the...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 24, 2022 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (“G2” or the “Company”) (TSXV:GTWO; OTCQX:GUYGF) is pleased to announce that it proposes to increase its previously announced non-brokered private placement to provide for the issuance of up to 6,800,000 units (the “Units”) at a price of $0.45 per Unit, for gross proceeds of up to $3,060,000 (the “Offering”). Each Unit shall be comprised of one common share (“Share”) of the Company and one common share purchase warrant (“Warrant”). Each Warrant entitles the holder, on exercise, to purchase one Share for a period of two years following issuance of the Warrant at an exercise price of $1.20 per Share. As announced on January 6, 2022, the Company has already closed the first tranche (the...